22 August 2017
Visiongain’s new report The Global Respiratory Inhalers Market, 2017-2027: Revenue prospects by Product Type (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers), By Indication (Asthma and COPD) and Geography 2017-2027 indicates that the Respiratory Inhalers market will see over $33bn in revenue in 2017.
The lead analyst of the report said:
“The advantages of inhalation therapy in the treatment of asthma and COPD have long since been established. In comparison to the oral and parenteral route, the drug dose required in inhalation therapy is lower and rapid onset of action is achieved with minimal unwanted systemic effects. The prevalence of asthma and COPD is growing across the globe and this is further fuelled by the growing ageing population. It is the major factor driving the growth of respiratory inhalers market. Other factors driving the market growth include technological advancements in respiratory inhalation products, growing awareness regarding respiratory diseases, and increasing disposable income in emerging economies.
However, growing pressure to reduce healthcare cost in the developed countries such as the U.S. is impeding the market growth. In addition, high cost of some types of inhalation devices (for instance, dry powder inhalers and nebulizers) is hindering the market growth in the respective product segments; especially in cost-sensitive markets. In addition to this, the market is likely to witness intense competition between generic and branded product manufacturers as some of the current blockbuster products are going off-patent across the forecast period. Thus, though sales will be increasing in terms of volume, the value market is likely to witness sluggish growth.”
The 181-page report contains 118 tables, charts and graphs that add visual analysis in order to explain developing trends within the Respiratory Inhalers. Visiongain provides revenue forecasts for the period 2017-2027 for the leading Respiratory Inhaler submarkets, segmented by product type, with forecasts for Metered Dose Inhalers, Dry Powder Inhalers (including single-dose and multi-dose DPIs) and Nebulizers (Jet, Ultrasonic and Vibrating-Mesh Nebulizers). The respiratory inhalers market is also segmented by Indication with forecasts for Asthma and COPD, as well as other respiratory conditions.
The 181-page report offers market forecasts and analysis for 12 national markets. In addition, the report contains a dedicated leading companies’ chapter covering 7 companies leading the field in respiratory inhaler market in detail.
The Global Respiratory Inhalers Market, 2017-2027: Revenue prospects by Product Type (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers), By Indication (Asthma and COPD) and Geography 2017-2027 report will be of value to anyone who wants to better understand the respiratory inhalers market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the respiratory inhalers industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth